Phenotypes associated with this allele

• Allele Symbol: Ripk3^tm1Arte
• Allele Name: targeted mutation 1, TaconicArtemis
• Allele ID: MGI:5614565
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^tm9(cre/ESR1)Arte/Gt(ROSA)26Sor^+ Ripk3^tm1Arte/Ripk3^tm1Arte	involves: C57BL/6NTac	MGI:5614626

Genotype
MGI:5614626

cn1

• Allelic Composition: Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺; Ripk3^tm1Arte/Ripk3^tm1Arte
• Genetic Background: involves: C57BL/6NTac

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

digestive/alimentary system

abnormal crypts of Lieberkuhn morphology ( J:209137 )

• mice treated with tamoxifen exhibit degeneration of intestinal crypts

blunted small intestinal villi ( J:209137 )

• mice treated with tamoxifen exhibit villous blunting

fused small intestinal villi ( J:209137 )

• mice treated with tamoxifen exhibit villous fusion

intestinal edema ( J:209137 )

• mice treated with tamoxifen exhibit segmental, submucosal edema in the large intestine

diarrhea ( J:209137 )

• mice treated with tamoxifen develop diarrhea

abnormal intestine physiology ( J:209137 )

• mice treated with tamoxifen exhibit increased apoptosis in the small intestine

intestinal inflammation ( J:209137 )

• mice treated with tamoxifen exhibit mild enteritis

endocrine/exocrine glands

abnormal crypts of Lieberkuhn morphology ( J:209137 )

• mice treated with tamoxifen exhibit degeneration of intestinal crypts

thymus atrophy ( J:209137 )

• mice treated with tamoxifen show thymic atrophy

growth/size/body

weight loss ( J:209137 )

• mice treated with tamoxifen lose between 13 and 28% of their body weight after 6 to 7 days

hematopoietic system

thymus atrophy ( J:209137 )

• mice treated with tamoxifen show thymic atrophy

abnormal lymphocyte morphology ( J:209137 )

• mice treated with tamoxifen exhibit pyknotic and karyorrhectic lymphocytes in secondary lymphoid organs

homeostasis/metabolism

intestinal edema ( J:209137 )

• mice treated with tamoxifen exhibit segmental, submucosal edema in the large intestine

immune system

intestinal inflammation ( J:209137 )

• mice treated with tamoxifen exhibit mild enteritis

thymus atrophy ( J:209137 )

• mice treated with tamoxifen show thymic atrophy

abnormal lymphocyte morphology ( J:209137 )

• mice treated with tamoxifen exhibit pyknotic and karyorrhectic lymphocytes in secondary lymphoid organs

mortality/aging

mortality/aging ( J:209137 )

N • mice treated with tamoxifen do not show signs of morbidity after 5 days